E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor

European Journal of Pharmacology

Volumn 548, Issue 1-3, 2006, Pages 181-187

  Yasuda, Nobuyuki ^a   Nagakura, Tadashi ^a   Inoue, Takashi ^a   Yamazaki, Kazuto ^a   Katsutani, Naruo ^a   Takenaka, Osamu ^a   Clark, Richard ^a   Matsuura, Fumiyoshi ^a   Emori, Eita ^a   Yoshikawa, Seiji ^a   Kira, Kazunobu ^a   Ikuta, Hironori ^a   Okada, Toshimi ^a   Saeki, Takao ^a   Asano, Osamu ^a   Tanaka, Isao ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Dipeptidyl peptidase 8; Dipeptidyl peptidase 9; Dipeptidyl peptidase IV; Glucagon like Peptide 1; Insulin

Indexed keywords

3 BUT 2 YNYL 5 METHYL 2 PIPERAZIN 1 YL 3,5 DIHYDRO 4H IMIDAZO[4,5 D]PYRIDAZIN 4 ONE TOSYLATE; E 3024; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD GLUCOSE; DIPEPTIDYL PEPTIDASES; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; DOGS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN-SECRETING CELLS; MALE; MICE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PROTEASE INHIBITORS; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RATS, ZUCKER; RECOMBINANT PROTEINS; TOSYL COMPOUNDS;

EID: 33748708415     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.011     Document Type: Article

References (21)

1. Ahren B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Bavenholm P., Efendic S., Eriksson J.W., Dickinson S., and Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25 (2002) 869-875
2. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 2078-2084
3. Balkan B., Kwasnik L., Miserendino R., Holst J.J., and Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42 (1999) 1324-1331
4. Burkey B.F., Li X., Bolognese L., Balkan B., Mone M., Russell M., Hughes T.E., and Wang P.R. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J. Pharmacol. Exp. Ther. 315 (2005) 688-695
5. Deacon C.F., Ahren B., and Holst J.J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?. Expert Opin. Investig. Drugs 13 (2004) 1091-1102
6. Demuth H.U., McIntosh C.H., and Pederson R.A. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 1751 (2005) 33-44
7. Drucker D.J. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin. Investig. Drugs 12 (2003) 87-100
8. Hansotia T., Baggio L.L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., and Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53 (2004) 1326-1335
9. Holst J.J., and Deacon C.F. Glucagon-like peptide 1 and inhibitors of in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 4 (2004) 589-596
10. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., Hickey G.J., Kowalchick J.E., Leiting B., Lyons K., Marsilio F., McCann M.E., Patel R.A., Petrov A., Scapin G., Patel S.B., Roy R.S., Wu J.K., Wyvratt M.J., Zhang B.B., Zhu L., Thornberry N.A., and Weber A.E. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48 (2005) 141-151
11. Lankas G.R., Leiting B., Roy R.S., Eiermann G.J., Beconi M.G., Biftu T., Chan C.C., Edmondson S., Feeney W.P., He H., Ippolito D.E., Kim D., Lyons K.A., Ok H.O., Patel R.A., Petrov A.N., Pryor K.A., Qian X., Reigle L., Woods A., Wu J.K., Zaller D., Zhang X., Zhu L., Weber A.E., and Thornberry N.A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54 (2005) 2988-2994
12. Marguet D., Baggio L., Kobayashi T., Bernard A.M., Pierres M., Nielsen P.F., Ribel U., Watanabe T., Drucker D.J., and Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl.Acad. Sci. U. S. A. 97 (2000) 6874-6879
13. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., Yoshikawa S., Asano O., and Tanaka I. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. 284 (2001) 501-506
14. Pederson R.A., White H.A., Schlenzig D., Pauly R.P., McIntosh C.H., and Demuth H.U. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 47 (1998) 1253-1258
15. Sorbera L.A., Revel L., and Castañer L. P32/98. Antidiabetic dipeptidyl peptidase IV inhibitor. Drugs Future 26 (2001) 859-864
16. Steinbrecher A., Reinhold D., Quigley L., Gado A., Tresser N., Izikson L., Born I., Faust J., Neubert K., Martin R., Ansorge S., and Brocke S. Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J. Immunol. 166 (2001) 2041-2048
17. Sudre B., Broqua P., White R.B., Ashworth D., Evans D.M., Haigh R., Junien J.L., and Aubert M.L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51 (2002) 1461-1469
18. Takasaki K., Iwase M., Nakajima T., Ueno K., Nomoto Y., Nakanishi S., and Higo K. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Eur. J. Pharmacol. 486 (2004) 335-342
19. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with anti-hyperglycemic properties. J. Med. Chem. 46 (2003) 2774-2789
20. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., and Tanaka I. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. J. Pharmacol. Exp. Ther. 310 (2004) 614-619
21. Yip R.G., and Wolfe M.M. GIP biology and fat metabolism. Life Sci. 66 (2000) 91-103